A new study led by researchers at Johns Hopkins Bloomberg School of Public Health estimates that thousands of lives could have been saved during the first year of the COVID-19 pandemic if convalescent plasma had been used more broadly, particularly in outpatients at high risk for severe disease and in hospitalized patients during their first few days of admission.
Teva to pay $450M to settle allegations of kickbacks and generic drug price-fixing
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS